-
公开(公告)号:US07223738B2
公开(公告)日:2007-05-29
申请号:US10510069
申请日:2003-04-04
申请人: Mark T. Bilodeau , Mark E. Duggan , John C. Hartnett , Craig W. Lindsley , Peter J. Manley , Zhicai Wu , Zhijian Zhao
发明人: Mark T. Bilodeau , Mark E. Duggan , John C. Hartnett , Craig W. Lindsley , Peter J. Manley , Zhicai Wu , Zhijian Zhao
IPC分类号: A01N43/04 , A01N43/58 , A01N43/60 , A01N43/42 , A61K31/70 , A61K31/50 , A61K31/495 , A61K31/52 , A61K31/47 , C07D487/00 , C07D491/00 , C07H15/00 , C07H17/00 , C07H17/02 , C09B25/00
CPC分类号: C07D401/10 , A61K31/498 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/14 , C07D409/14 , C07D417/14 , C07D471/04
摘要: The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
-
公开(公告)号:US07579355B2
公开(公告)日:2009-08-25
申请号:US10554001
申请日:2004-04-20
申请人: Mark T. Bilodeau , Mark E. Duggan , John C. Hartnett , Craig W. Lindsley , Zhicai Wu , Zhijian Zhao
发明人: Mark T. Bilodeau , Mark E. Duggan , John C. Hartnett , Craig W. Lindsley , Zhicai Wu , Zhijian Zhao
IPC分类号: A61K31/52 , C07D401/14
CPC分类号: C07F9/65583 , A61K45/06 , C07D401/04 , C07D401/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D487/04
摘要: The present invention is directed to compounds which contain a substituted pyridine moeity which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
摘要翻译: 本发明涉及含有抑制Akt(丝氨酸/苏氨酸蛋白激酶)活性的取代吡啶甲氧基化合物。 本发明还涉及含有本发明化合物的治疗组合物和治疗癌症的方法,包括施用本发明化合物。
-
公开(公告)号:US07414055B2
公开(公告)日:2008-08-19
申请号:US10554187
申请日:2004-04-20
申请人: Mark E. Duggan , Craig W. Lindsley , Zhicai Wu , Zhijian Zhao , John C. Hartnett
发明人: Mark E. Duggan , Craig W. Lindsley , Zhicai Wu , Zhijian Zhao , John C. Hartnett
IPC分类号: A61K31/44 , C07D401/02
CPC分类号: C07D213/85 , C07D401/04 , C07D401/12 , C07D401/14 , C07D413/12 , C07D417/04 , C07D417/12 , C07D417/14
摘要: The present invention is directed to compounds which contain a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
摘要翻译: 本发明涉及含有抑制Akt(丝氨酸/苏氨酸蛋白激酶)活性的取代的吡啶部分的化合物。 本发明还涉及含有本发明化合物的治疗组合物和治疗癌症的方法,包括施用本发明化合物。
-
公开(公告)号:US07304063B2
公开(公告)日:2007-12-04
申请号:US10554186
申请日:2004-04-20
IPC分类号: C07D401/10 , C07D403/10 , A61K31/53 , A61P35/00 , C07D253/06
CPC分类号: C07D417/14 , C07D253/065 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14
摘要: The present invention is directed to compounds which contain a heterocyclic triazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
摘要翻译: 本发明涉及含有抑制Akt(丝氨酸/苏氨酸蛋白激酶)活性的杂环三嗪部分的化合物。 本发明还涉及含有本发明化合物的治疗组合物和治疗癌症的方法,包括施用本发明化合物。
-
公开(公告)号:US07399764B2
公开(公告)日:2008-07-15
申请号:US10530252
申请日:2003-10-24
申请人: Mark E. Duggan , Craig W. Lindsley , Zhijian Zhao
发明人: Mark E. Duggan , Craig W. Lindsley , Zhijian Zhao
IPC分类号: A61K31/50 , A61K31/497 , C07D241/00 , C07D487/00
CPC分类号: A61K31/495 , A61K45/06 , C07D487/04 , C07D495/04
摘要: The present invention is directed to compounds which contain a five-membered heterocyclic ring fused to a substituted pyrazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
摘要翻译: 本发明涉及含有与被抑制Akt(丝氨酸/苏氨酸蛋白激酶)活性的取代吡嗪部分稠合的五元杂环的化合物。 本发明还涉及含有本发明化合物的治疗组合物和治疗癌症的方法,包括施用本发明化合物。
-
公开(公告)号:US07825135B2
公开(公告)日:2010-11-02
申请号:US10593950
申请日:2005-03-23
申请人: Wesley Blackaby , Mark E. Duggan , David Hallett , George D. Hartman , Andrew S. Jennings , William H. Leister , Richard T. Lewis , Craig W. Lindsley , Elizabeth Naylor , Leslie J. Street , Yi Wang , David D. Wisnoski , Scott E. Wolkenberg , Zhijian Zhao
发明人: Wesley Blackaby , Mark E. Duggan , David Hallett , George D. Hartman , Andrew S. Jennings , William H. Leister , Richard T. Lewis , Craig W. Lindsley , Elizabeth Naylor , Leslie J. Street , Yi Wang , David D. Wisnoski , Scott E. Wolkenberg , Zhijian Zhao
IPC分类号: A61K31/435 , A61K31/445
CPC分类号: C07D409/14 , C07D401/04 , C07D401/14 , C07D413/14
摘要: The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
摘要翻译: 本发明涉及抑制甘氨酸转运蛋白GlyT1的吡啶基,哒嗪基,嘧啶基和吡嗪基哌啶化合物,其可用于治疗与甘氨酸能或谷氨酸能神经传递功能障碍相关的神经和精神疾病以及其中涉及甘氨酸转运蛋白GlyT1的疾病 。
-
公开(公告)号:US07524850B2
公开(公告)日:2009-04-28
申请号:US11704105
申请日:2007-02-08
申请人: Mark E. Duggan , Craig W. Lindsley , Zhijian Zhao
发明人: Mark E. Duggan , Craig W. Lindsley , Zhijian Zhao
IPC分类号: A61K31/4965 , C07D401/14
CPC分类号: C07D401/14 , C07D241/18
摘要: The compounds of Formula E are useful as anti-cancer agents:
摘要翻译: 式E的化合物可用作抗癌剂:
-
公开(公告)号:US07507836B2
公开(公告)日:2009-03-24
申请号:US10550968
申请日:2004-03-22
IPC分类号: C07D209/48 , C07C233/05 , A61K31/40 , A61K31/165
CPC分类号: C07D417/12 , C07D209/48 , C07D213/81 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D513/04
摘要: The present invention is directed to compounds which are allosteric modulators of metabotropic glutamate receptors, including the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
摘要翻译: 本发明涉及代谢型谷氨酸受体的变构调节剂(包括mGluR5受体)的化合物,它们可用于治疗或预防与谷氨酸能力障碍相关的神经和精神疾病以及涉及代谢型谷氨酸受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。
-
公开(公告)号:US07947714B2
公开(公告)日:2011-05-24
申请号:US12084027
申请日:2006-10-27
申请人: David Hallett , Craig W. Lindsley , Elizabeth M. Naylor , Zhijian Zhao , Cory R. Theberge , Scott E. Wolkenberg , M. Brad Nolt
发明人: David Hallett , Craig W. Lindsley , Elizabeth M. Naylor , Zhijian Zhao , Cory R. Theberge , Scott E. Wolkenberg , M. Brad Nolt
IPC分类号: A61K31/445 , C07D211/32
CPC分类号: C07D211/96 , C07D401/04 , C07D405/06
摘要: The present invention is directed to piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
摘要翻译: 本发明涉及抑制甘氨酸转运蛋白GlyT1的哌啶化合物,其可用于治疗与甘氨酸能或谷氨酸能神经传递功能障碍相关的神经和精神疾病以及其中涉及甘氨酸转运蛋白GlyT1的疾病。
-
公开(公告)号:US20090258853A1
公开(公告)日:2009-10-15
申请号:US12225027
申请日:2007-03-09
IPC分类号: A61K31/4709 , C07D401/14 , A61K31/506
CPC分类号: C07D409/14 , C07D401/04 , C07D401/12 , C07D401/14 , C07D417/14
摘要: This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy, neuropathy and nephropathy. Many of the compounds are orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostatin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof.
摘要翻译: 本发明涉及作为生长抑素的激动剂并且对生长抑素受体亚型SSTR2有选择性的化合物。 该化合物可用于治疗和预防糖尿病以及糖尿病相关病理学,包括视网膜病变,神经病变和肾病。 许多化合物是口服活性的。 因此,本发明的目的是描述这些化合物。 进一步的目的是描述生长抑素激动剂的具体优选的立体异构体。 另一个目的是描述制备这些化合物的方法。 另一个目的是描述使用这些化合物作为其活性成分的方法和组合物。
-
-
-
-
-
-
-
-
-